1h Free Analyst Time
The Shingles Vaccine Market grew from USD 1.73 billion in 2023 to USD 1.87 billion in 2024. It is expected to continue growing at a CAGR of 8.11%, reaching USD 2.99 billion by 2030. Speak directly to the analyst to clarify any post sales queries you may have.
The shingles vaccine market is characterized by its critical role in preventing and mitigating herpes zoster infections, predominantly affecting individuals over 50 and immunocompromised patients. The vaccine's necessity stems from its efficacy in reducing both incidence and severity of shingles and postherpetic neuralgia, greatly impacting patient quality of life and healthcare costs. Its application largely spans across healthcare settings like clinics, hospitals, and pharmacies, serving the adult segment significantly more than younger populations. The market's growth is primarily driven by the increasing aging global population, heightened awareness about preventive healthcare, and advancements in vaccine technology. However, the market is met with challenges such as vaccine hesitancy, high development costs, supply chain complexities, and stringent regulatory landscapes, which sometimes delay the introduction of new products. Market insights suggest a promising expansion potential, particularly in emerging economies where healthcare infrastructure is rapidly developing, and vaccination programs are gaining momentum. Opportunities also lie in differential pricing strategies and personalization approaches to penetrate untapped segments. A significant area for innovation is the development of vaccines with broader age approvals, enhanced safety profiles, and prolonged effectiveness, which could meet both safety demands and convenience, thus mitigating some of the hesitancy issues. Collaborations between pharmaceutical companies and tech firms for enhanced vaccine delivery solutions and tracking systems can also spur growth. As companies seek to balance affordability and accessibility with profitability, an emphasis on fostering public-private partnerships could facilitate better vaccine distribution and awareness campaigns. While the market presents abundant growth opportunities, addressing the inherent challenges with strategic innovation and targeted outreach can create sustainable business momentum within the dynamic landscape of the shingles vaccine market.
Understanding Market Dynamics in the Shingles Vaccine Market
The Shingles Vaccine Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.- Market Drivers
- Increasing prevalence of chronic diseases
- Rising number of geriatric population worldwide
- Rising awareness about shingles health risks and growing focus on immunization
- Market Restraints
- High capital requirements for vaccine development
- Market Opportunities
- Ongoing Research & development initiatives on shingles vaccines
- Significantly increasing public health expenditure worldwide
- Market Challenges
- Adverse effects associated with shingles vaccines
Exploring Porter’s Five Forces for the Shingles Vaccine Market
Porter’s Five Forces framework further strengthens the insights of the Shingles Vaccine Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.Applying PESTLE Analysis to the Shingles Vaccine Market
External macro-environmental factors deeply influence the performance of the Shingles Vaccine Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.Analyzing Market Share in the Shingles Vaccine Market
The Shingles Vaccine Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.Evaluating Vendor Success with the FPNV Positioning Matrix in the Shingles Vaccine Market
The Shingles Vaccine Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.Strategic Recommendations for Success in the Shingles Vaccine Market
The Shingles Vaccine Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.Key Company Profiles
The report delves into recent significant developments in the Shingles Vaccine Market, highlighting leading vendors and their innovative profiles. These include Astellas Pharma Inc., Barinthus Biotherapeutics plc, Bavarian Nordic, Biogenetech Co., Ltd., CanSino Biologics Inc., CSL Limited, Curevo Inc., Daiichi Sankyo Company, Limited, Dynavax Technologies Corporation, Emergent Biosolutions Inc., GeneOne Life Science, Inc., Gilead Sciences, Inc., GlaxoSmithKline PLC, Inovio Pharmaceuticals, Inc., JCR Pharmaceuticals Co., Ltd., Jiangsu Recbio Technology Co., Ltd., Merck KGaA, Moderna, Inc., Pfizer Inc., Sanofi S.A., Sinovac Biotech Ltd., SK Chemicals, Takeda Pharmaceutical Company Limited, Valneva SE, and VBI Vaccines Inc..Market Segmentation & Coverage
This research report categorizes the Shingles Vaccine Market to forecast the revenues and analyze trends in each of the following sub-markets:- Product
- SkyZoster
- Zostavax
- Shingrix
- Type
- Live Attenuated Vaccine
- Recombinant Vaccine
- Distribution Channel
- Healthcare Centers
- Pharmacies
- Region
- Americas
- Argentina
- Brazil
- Canada
- Mexico
- United States
- California
- Florida
- Illinois
- New York
- Ohio
- Pennsylvania
- Texas
- Asia-Pacific
- Australia
- China
- India
- Indonesia
- Japan
- Malaysia
- Philippines
- Singapore
- South Korea
- Taiwan
- Thailand
- Vietnam
- Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom
- Americas
The report provides a detailed overview of the market, exploring several key areas:
- Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
- Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
- Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
- Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
- Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.
Additionally, the report addresses key questions to assist stakeholders in making informed decisions:
- What is the current size of the market, and how is it expected to grow?
- Which products, segments, and regions present the most attractive investment opportunities?
- What are the prevailing technology trends and regulatory factors influencing the market?
- How do top vendors rank regarding market share and competitive positioning?
- What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?
Table of Contents
1. Preface
2. Research Methodology
4. Market Overview
5. Market Insights
6. Shingles Vaccine Market, by Product
7. Shingles Vaccine Market, by Type
8. Americas Shingles Vaccine Market
9. Asia-Pacific Shingles Vaccine Market
10. Europe, Middle East & Africa Shingles Vaccine Market
11. Competitive Landscape
12. Competitive Portfolio
13. Appendix
List of Figures
List of Tables
Companies Mentioned
The leading players in the Shingles Vaccine market, which are profiled in this report, include:- Astellas Pharma Inc.
- Barinthus Biotherapeutics plc
- Bavarian Nordic
- Biogenetech Co., Ltd.
- CanSino Biologics Inc.
- CSL Limited
- Curevo Inc.
- Daiichi Sankyo Company, Limited
- Dynavax Technologies Corporation
- Emergent Biosolutions Inc.
- GeneOne Life Science, Inc.
- Gilead Sciences, Inc.
- GlaxoSmithKline PLC
- Inovio Pharmaceuticals, Inc.
- JCR Pharmaceuticals Co., Ltd.
- Jiangsu Recbio Technology Co., Ltd.
- Merck KGaA
- Moderna, Inc.
- Pfizer Inc.
- Sanofi S.A.
- Sinovac Biotech Ltd.
- SK Chemicals
- Takeda Pharmaceutical Company Limited
- Valneva SE
- VBI Vaccines Inc.
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 193 |
| Published | October 2024 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value ( USD | $ 1.87 Billion |
| Forecasted Market Value ( USD | $ 2.99 Billion |
| Compound Annual Growth Rate | 8.1% |
| Regions Covered | Global |
| No. of Companies Mentioned | 26 |
